Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025

Builds On Initial 2018 Agreement While Aligning With Fresenius Kabi’s 2026 Vision

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.

Sarunyu_foto/Shutterstock.com

Spanish biosimilars developer mAbxience will look to expand its global footprint after penning a further agreement with Abbott allowing the US giant to commercialize several of mAbxience’s biosimilars in “key emerging countries,” including in Latin America, Southeast Asia, the Middle East and Africa.

Key Takeaways:

  • Abbott will register and commercialize several mAbxience biosimilars in “key emerging countries”

Focusing on oncology, women’s health and respiratory diseases, the first biosimilars are expected to launch in 2025, the firms disclosed,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.